RSV Vaccine Proves Highly Effective for Older Adults in Landmark Study

**A comprehensive multi-state study**, published in *The Lancet*, has analyzed the real-world effectiveness of the RSV (Respiratory Syncytial Virus) vaccine. Conducted by the VISION Network, the study focuses on older adults during the 2023-24 respiratory disease season, following the vaccine's approval in the U.S. **The findings reveal that the vaccine provides approximately 80% protection against severe disease and hospitalization**. Notably, individuals 75 and older, who are at the highest risk, benefit significantly from the vaccine. The study consists of data from the CDC and various geographically diverse healthcare systems, highlighting the power of big data in assessing vaccine effectiveness, a gap not addressed by the initial clinical trials. Dr. Shaun Grannis, co-author and family practice physician, emphasizes the importance of vaccination for older adults as a preventive measure. **RSV affects the respiratory system, leading to substantial illness and death, specifically during seasonal epidemics**. Previously, up to 160,000 RSV-related hospitalizations and 10,000 deaths occurred annually among older U.S. adults. Dr. Brian Dixon highlights the impressive effectiveness rate compared to other vaccines like influenza. He points to the essential role of studies like this in understanding and implementing prevention techniques. **Given that the annual cost of RSV hospitalizations ranges from $1.2 to $5 billion**, preventing a large percentage of these could result in significant savings. The VISION Network study involved institutions such as Permanente Northwest, University of Colorado, Intermountain Healthcare, and others across 230 hospitals and 245 emergency departments. Key contributors include researchers from the Regenstrief Institute and Indiana University School of Medicine.